Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-02-11

Clinical Trial Update: A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the efficacy and safety of midostaurin in newly diagnosed FLT3-mutated acute myeloid leukemia has completed enrollment and posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Midostaurin (midostaurin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2025-02-11